Page 31 - Product Testing News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at ... Metacrine, Inc.March 11, 2021 GMT SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that final result...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from PR Newswire. The AP news staff was not involved in its creation. Astellas Submits New Drug Application for Enfortumab Vedotin in Japan March 11, 2021 GMT Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.) Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.) TOKYO, March 11, 2021 /PRNewswire/ -- Astellas Pharm...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ... BioXcel TherapeuticsMarch 11, 2021 GMT New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL50...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ascendis Pharma A/S Reports Full Year 2020 Financial Results Ascendis PharmaMarch 10, 2021 GMT – Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track – – Oncology pipeline advancing into clinical trials beginning with TransCon TLR7/8 Agonist – – – COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) --...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, ... Surface Oncology, Inc.March 9, 2021 GMT CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collabor...

Press release content from Business Wire. The AP news staff was not involved in its creation. Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates March 9, 2021 GMT BEDFORD, Mass.--(BUSINESS WIRE)--Mar 9, 2021-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended De...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma Allarity Therapeutics A/SMarch 9, 2021 GMT - Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release   Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today ann...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation. DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke March 9, 2021 GMT MINNEAPOLIS--(BUSINESS WIRE)--Mar 9, 2021-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion leader (KOL) webinar on DM199, the C...